Literature DB >> 15516290

Urine concentrations of fentanyl and norfentanyl during application of Duragesic transdermal patches.

Alphonse Poklis1, Ronald Backer.   

Abstract

A study of the urinary concentration of fentanyl (F) and its major metabolite norfentanyl (NF) in chronic pain patients treated with the Duragesic continuous release transdermal patches is presented. These patches are available in 10, 20, 30, and 40 cm(2) sizes releasing 25, 50, 75, and 100 microg/h F, respectively. F is rapidly and extensively metabolized, with NF as the major metabolite. Five hundred-forty six random urine specimens were collected from chronic pain patients wearing 25, 50, 75, or 100 ug F transdermal patches. Urine specimens were collected from hours after application to several days later after continuous F release. Each specimen was analyzed for F, NF, creatinine, and pH. Additionally, each was screened by enzyme immunoassay for the following: amphetamines, barbiturates, benzodiazepines, cocaine metabolite, methadone, phencyclidine, d-propoxyphene, opiates, and marijuana metabolites. All positive screening results were confirmed by gas chromatography-mass spectrometry (GC-MS). F and NF were isolated from urine by solid-phase extraction then identified and quantified by GC-MS in SIM mode. The LODs and LOQs for F and NF were 3 ng/mL, respectively. The results of F and NF analysis of urine form those wearing 25-microg patches (N = 142) was mean F, 47 ng/mL with a range of 0 to 983 ng/mL, and 97% of the specimens contained < 200 ng/mL and mean NF, 175 ng/mL with a range of 0-980 ng/mL, while 95% of the specimens contained < 400 ng/mL. The results of F and NF analysis of urine form those wearing 50 microg patches (N = 184) was: mean F, 74 ng/mL with a range of 0 to 589 ng/mL, and 92% of the specimens contained < 200 ng/mL and mean NF, 257 ng/mL with a range of 0-2200 ng/mL, and 98% of the specimens contained < 1000 ng/mL. The results of F and NF analysis of urine form those wearing 75 microg patches (N = 85) was mean F, 107 ng/mL with a range of 0 to 1280 ng/mL, and 98% of the specimens contained < 400 ng/mL and mean NF, 328 ng/mL with a range of 0-5630 ng/mL, and 99% of the specimens contained < 1000 ng/mL. The results of F and NF analysis of urine form those wearing 100 ug patches (N = 135) was mean F, 100 ng/mL with a range of 0 to 1080 ng/mL, while 96% of the specimens contained < 400 ng/mL and mean NF, 373 ng/mL with a range of 0-5730 ng/mL, and 95% of the specimens contained < 1000 ng/mL. The incidence of other drugs detected as a percentage the specimens was opiates, 48%, benzodiazepines, 43%; barbiturates, 3%; methadone, 4%; marijuana metabolite, 3%; and cocaine metabolite, 1%. With the exception of F and/or NF, no other drugs were detected in 25% of the specimens. These data demonstrate the wide variation in concentrations of F and NF in random urine specimens following application of Duragesic patches. However, these values obtained during therapeutic use far exceed concentrations previously reported in fatal poisoning. In general, one may expect to find urine NF concentrations 3-4 times higher than those of F.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15516290     DOI: 10.1093/jat/28.6.422

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  9 in total

Review 1.  Laboratory testing for prescription opioids.

Authors:  Michael C Milone
Journal:  J Med Toxicol       Date:  2012-12

2.  Toxicological testing when evaluating fatal cases suspected of acute fentanyl toxicity.

Authors:  Xiulu Ruan; Srinivas Chiravuri; Alan D Kaye
Journal:  Forensic Sci Med Pathol       Date:  2016-07-07       Impact factor: 2.007

Review 3.  Fentanyl Formulations in the Management of Pain: An Update.

Authors:  Stephan A Schug; Sonya Ting
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

4.  Assisted suicide by fentanyl intoxication due to excessive transdermal application.

Authors:  Martin Juebner; Mathias Fietzke; Justus Beike; Markus A Rothschild; Katja Bender
Journal:  Int J Legal Med       Date:  2014-02-28       Impact factor: 2.686

5.  Quantitative low-volume assay for simultaneous determination of fentanyl, norfentanyl, and minor metabolites in human plasma and urine by liquid chromatography-tandem mass spectrometry (LC-MS/MS).

Authors:  Nina Sophia Mahlke; Victoria Ziesenitz; Gerd Mikus; Gisela Skopp
Journal:  Int J Legal Med       Date:  2014-07-06       Impact factor: 2.686

6.  Development and Clinical Validation of a Sensitive Lateral Flow Assay for Rapid Urine Fentanyl Screening in the Emergency Department.

Authors:  Zhao Li; Hui Chen; Sheng Feng; Kengku Liu; Ping Wang
Journal:  Clin Chem       Date:  2020-02-01       Impact factor: 8.327

7.  Expected and actual fentanyl exposure among persons seeking opioid withdrawal management.

Authors:  Shannon R Kenney; Bradley J Anderson; Micah T Conti; Genie L Bailey; Michael D Stein
Journal:  J Subst Abuse Treat       Date:  2018-01-04

8.  Protracted renal clearance of fentanyl in persons with opioid use disorder.

Authors:  Andrew S Huhn; J Gregory Hobelmann; George A Oyler; Eric C Strain
Journal:  Drug Alcohol Depend       Date:  2020-07-02       Impact factor: 4.492

9.  Accurate prediction of terahertz spectra of molecular crystals of fentanyl and its analogs.

Authors:  Chun-Hung Wang; Anthony C Terracciano; Artёm E Masunov; Mengyu Xu; Subith S Vasu
Journal:  Sci Rep       Date:  2021-02-18       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.